Tucatinib/tucatinib storage conditions requirements

Tucatinib is an oral small molecule targeted drug. Reasonable storage conditions are crucial to maintaining drug activity and safety. According to overseas drug guidance, tucatinib should be stored at a controlled room temperature of 20°C to 25°C (68°F to 77°F), while short-term excursions in the range of 15°C to 30°C (59°F to 86°F) are allowed. Strictly maintaining a stable temperature helps avoid drug decomposition or decrease in activity, thereby ensuring the efficacy and safety of each dose.

Tucatinib must be stored in the original container, and the bottle cap should be tightened after each withdrawal to prevent moisture from entering and affecting the stability of the tablets. There is usually a desiccant inside the medicine bottle to control humidity, so do not throw it away. The original container is designed to be moisture-proof and light-proof, effectively protecting the medicine in its best condition throughout the treatment cycle. After opening the bottle, patients should complete the use of the medicine within three months. Even if the tablets have not been taken completely after three months, the remaining medicine should be discarded to ensure the safety and efficacy of the medicine.

In addition, during daily use, tucatinib should be avoided in bathrooms or high-humidity environments, and should not be placed in places with large temperature fluctuations such as cars to prevent the tablets from becoming damp or losing activity due to heat. Children and pets should avoid contact with the drug to ensure family safety. Although storage conditions may seem simple, they are of great significance to the long-term efficacy and adverse reaction management of targeted drugs.

In short, the storage management of tucatinib is an important part of safe medication. Strict compliance with temperature, humidity and bottle opening time requirements can ensure that the drug exerts its best effect throughout the entire course of treatment. For patients, understanding and implementing these storage conditions can not only improve efficacy, but also reduce the risk of side effects caused by drug degradation. It is also an important guarantee for the long-term management of HER2-positive advanced breast cancer and colorectal cancer.

Reference materials:https://www.tukysa.com/